Physician profile
Michael Castro
NPI 1639170293
$16,279.28
in general payments reported to CMS, 2019-2025
67 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,423 · 2020: $1,681 · 2021: $2,526 · 2022: $3,659 · 2023: $3,140 · 2024: $2,208 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,671 · Consulting Fee: $300 · Entertainment: $19.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,670.92 |
| Consulting Fee | $300.00 |
| Entertainment | $19.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,363.61 | 2019-2024 | Repatha, Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $2,315.08 | 2019-2024 | Breztri, Farxiga, Wainua |
| Novo Nordisk INC | $1,726.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,133.84 | 2019-2024 | Ubrelvy, Qulipta, Synthroid |
| Pfizer INC. | $697.34 | 2019-2024 | |
| Boston Scientific Corporation | $691.33 | 2019-2025 | General - Brady, Watchman Flx, Watchman Access System |
| Abbott Laboratories | $669.69 | 2019-2024 | Mitraclip, Amplatzer Talisman, Freestyle Libre 2 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $517.96 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $415.53 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Lucid Diagnostics INC. | $323.85 | 2021-2023 | |
| Penumbra, INC. | $297.02 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $296.52 | 2019-2023 | |
| Medtronic, INC. | $272.55 | 2022-2024 | Abre, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $260.19 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.60 | 2019-2023 | Jardiance |
Show all 65 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.